1. 湖南中医药大学中医诊断研究所/湖南2011数字中医药协同创新中心
2. 抗肿瘤中药创制技术湖南省工程研究中心
3. 深圳大学第一附属医院
4. 广东医学院附属福田医院
纸质出版:2016
移动端阅览
[1]谢梦洲,贺佐梅,黄飞娟,周小青,吴正治.胃癌脾虚证唾液蛋白指纹图谱分子诊断模型研究[J].中医杂志,2016,57(22):1949-1953.
XIE Mengzhou, HE Zuomei, HUANG Feijuan, et al. Molecular Diagnostic Model of Saliva Protein Fingerprints in Gastric Cancer Patients with Spleen Deficiency[J]. Journal of Traditional Chinese Medicine2016, 57(22): 1949-1953.
[1]谢梦洲,贺佐梅,黄飞娟,周小青,吴正治.胃癌脾虚证唾液蛋白指纹图谱分子诊断模型研究[J].中医杂志,2016,57(22):1949-1953. DOI: 10.13288/j.11-2166/r.2016.22.015.
XIE Mengzhou, HE Zuomei, HUANG Feijuan, et al. Molecular Diagnostic Model of Saliva Protein Fingerprints in Gastric Cancer Patients with Spleen Deficiency[J]. Journal of Traditional Chinese Medicine2016, 57(22): 1949-1953. DOI: 10.13288/j.11-2166/r.2016.22.015.
目的研究建立胃癌脾虚证唾液蛋白质指纹图谱新型分子诊断模型。方法采集未经手术和放化疗治疗的57例胃癌患者(脾虚证组40例
非脾虚证组17例)、45例健康志愿者(正常对照组)的唾液标本
用弱阳离子交换型(WCX)纳米磁珠联合基质辅助激光解析离子化飞行时间质谱(MALDI-TOF MS)技术进行检测
获得各组标本的蛋白指纹图谱。比较各组唾液蛋白质质谱数据
找出胃癌脾虚证组与正常对照组、胃癌脾虚证组与胃癌非脾虚证组之间具有统计学意义的差异表达蛋白质峰;采用决策树算法计算出多个变量即质荷比(m/z)变化对两组样本的判别价值
确定最优化的诊断模型。结果胃癌脾虚证组与正常对照组唾液蛋白质质谱比较共有106个差异蛋白质峰有统计学意义
胃癌脾虚证组与胃癌非脾虚证组唾液蛋白质质谱比较共有6个差异蛋白质峰有统计学意义(P<0.05或P<0.01)。筛选建立了由m/z为5439.67、2411.67、3619.18共3个主要差异蛋白峰组成的胃癌脾虚证诊断模型;临床回代检验该模型的灵敏度和特异度分别达100%和93%;交叉验证法进一步验证诊断模型的灵敏度和特异度分别为87%和89%。结论基于WCX纳米磁珠结合MALDI-TOF-MS技术建立的胃癌脾虚证唾液蛋白质组无创性分子诊断模型敏感性高、特异性强
对胃癌脾虚证的诊断具有良好效率。
Objective To study and establish a new molecular diagnostic model of saliva protein fingerprints in gastic cancer patients with spleen deficiency. Methods Saliva samples of 57 gastric cancer patients with no surgery and chemoradiotherapy( 40 cases of spleen deficiency
17 non-spleen deficiency) and 45 healthy volunteers were collected and tested by weak cation exchange( WCX) magnetic nanoparticles combined with matrix-assisted laser desorption / ionization time of flight mass spectrometry( MALDI-TOF MS) to get the protein fingerprints of each group. Then the data were compared to figure out the differentially expressed protein peaks with statistical significance between gastric cancer spleen deficiency group and normal control group as well as that between gastric cancer spleen deficiency group and gastric cancer non-spleen deficiency group. The discriminant value of the variation of several variables
including mass-to-charge ratios( m / z)
to two group samples were calculated by decision tree algorithm
and the optimal diagnostic model was determined. Results There were 106 differentially expressed protein peaks with statistical significance in the saliva protein mass spectrum comparation between gastric cancer spleen deficiency group and normal control group
and 6 between gastric cancer spleen deficiency group and gastric cancer non-spleen-deficiency group( P < 0. 05 or P < 0. 01). Three main different protein peaks with m / z 5439. 67
2411. 67
3619. 18 were screened to establish the diagnostic model of gastric cancer spleen deficiency. The sensibility and specificity of the model are 100% and 93% respectively in clinical regression tests
which are further validated to be 87% and 89% in cross-validation. Conclusions Based on WCX magnetic nanoparticles combined with MALDI-TOF MS technology
the non-invasive saliva protein molecular diagnostic model of gastric cancer spleen deficiency has high sensibility and specificity
and it seems to have excellent efficiency to diagnose gastric cancer spleen deficiency.
0
浏览量
215
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号